Prelude Therapeutics Incorporated (NasdaqGS: PRLD)
Health Care · Biotechnology · US
$6.47
-2.41% today · +422.0% 1Y
Prelude Therapeutics Incorporated (NasdaqGS: PRLD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $682.86M and employs 79 people.
Over the last twelve months the share price has gained 422.0%, trading between 0.98 and 6.82.
Tweenvest scores Prelude Therapeutics Incorporated across four factors: quality 28/100, value 60/100. Its strongest factor is value.
PRLD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $682.86M
- Revenue (TTM)
- $22.42M
- P/E
- —
- EPS
- -0.72
- Dividend yield
- —
- Beta (5Y)
- 0.94
- 52-week high
- $6.82
- 52-week low
- $0.98
- Avg volume (3M)
- —
- Shares outstanding
- 102.99M
- Employees
- 79
- Next earnings
- —
About Prelude Therapeutics Incorporated
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
- ISIN
- US74065P1012
- Founded
- 2016
- Listed since
- Sep 25, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.29 | -0.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.10 | +0.06% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.96 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $549.00 | +0.26% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $834.94 | +0.78% |
| argenx SEENXTBR: ARGX | $63.06B | €872.20 | +0.93% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $142.50 | +2.60% |
Figures last refreshed Aug 18, 2026.